Helix BioPharma Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HBPCF research report →
Companywww.helixbiopharma.com
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2.
- CEO
- Thomas Mehrling
- IPO
- 2009
- Employees
- 7
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $130.61M
- P/E
- -29.67
- P/S
- 0.00
- P/B
- 8.10
- EV/EBITDA
- -31.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -36.79%
- ROIC
- -26.22%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-5,000,000 · -53872.37%
- EPS
- $0.00 · 100.00%
- Op Income
- $-5,000,000
- FCF YoY
- 23.56%
Performance & Tape
- 52W High
- $1.73
- 52W Low
- $0.60
- 50D MA
- $1.73
- 200D MA
- $1.41
- Beta
- -0.31
- Avg Volume
- 18
Get TickerSpark's AI analysis on HBPCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HBPCF Coverage
We haven't published any research on HBPCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HBPCF Report →